| Literature DB >> 22180786 |
Scott A Weisenberg1, Audrey N Schuetz, Elizabeth L Alexander, Elizabeth A Alexander, Brain Eiss, Maryam Behta, Lisa Saiman, Davise H Larone, Stephen G Jenkins, Kyu Y Rhee.
Abstract
BACKGROUND: Acinetobacter baumannii is an increasingly multidrug-resistant (MDR) cause of hospital-acquired infections, often associated with limited therapeutic options. We investigated A. baumannii isolates at a New York hospital to characterize genetic relatedness.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22180786 PMCID: PMC3236744 DOI: 10.1371/journal.pone.0028566
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Study Isolates.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 | 68F | 9/5 | A ICU | S | S | S | S | S | R | S | RESP | ||
| 2 | 48M | 2/29 | A ICU | R | R | R | R | R | R | I | 0.8 | 4 | RESP |
| 3 | 12F | 9/26 | B ICU | S | S | S | S | S | S | S | RESP | ||
| 4 | 18F | 8/3 | B ICU | S | S | S | S | S | S | S | 0.5 | RESP | |
| 5 | 58M | 10/8 | C ICU | S | S | I | S | R | R | I | RESP | ||
| 6 | 40F | 7/30 | B WARD | S | S | S | S | S | S | S | URINE | ||
| 7 | 79F | 8/24 | D ICU | S | S | S | S | S | S | S | RESP | ||
| 8 | 76M | 9/22 | E ICU | S | R | R | R | R | R | R | 1 | 12 | RESP |
| 9 | 76F | 10/26 | C ICU | R | R | R | R | I | R | I | 0.75 | 4 | RESP |
| 10 | 71M | 11/7 | D WARD | R | R | R | R | R | R | R | 1 | 12.5 | BLOOD |
| 11 | 3F | 8/8 | B ICU | R | R | R | R | R | R | I | 1.5 | 3 | RESP |
| 12 | 6M | 9/15 | A ICU | R | R | R | R | S | R | I | 1.5 | 3 | URINE |
| 13 | 78F | 7/13 | D WARD | S | R | R | R | R | S | S | 1 | 3 | URINE |
| 14 | 46F | 6/24 | D ICU | R | R | R | R | R | R | R | 4 | 2 | BLOOD |
| 15 | 67M | 9/20 | E ICU | R | R | R | R | I | R | R | 1 | 2 | RESP |
| 16 | 67M | 9/2 | A WARD | R | R | R | S | I | R | I | 1.5 | 3 | URINE |
| 17 | 34M | 11/23 | A ICU | R | R | R | R | R | R | R | 2 | 4 | RESP |
| 18 | 71F | 10/26 | A ICU | R | R | R | R | I | R | I | 0.5 | 2 | BLOOD |
| 19 | 62M | 12/6 | D ICU | R | R | R | R | R | R | R | 0.5 | 6 | RESP |
| 20 | 87F | 11/5 | F WARD | R | R | R | R | R | R | R | 0.5 | 8 | BLOOD |
| 21 | 78M | 11/30 | E WARD | R | R | R | R | R | R | R | 2 | 2 | BLOOD |
| 22 | 65F | 9/20 | E ICU | R | R | R | R | S | R | R | 0.75 | 2 | BLOOD |
| 23 | 43M | 8/18 | A ICU | R | R | R | R | S | R | I | 32 | 4 | RESP |
| 24 | 76M | 8/10 | E ICU | R | R | R | R | R | R | I | 0.5 | 2 | BLOOD |
| 25 | 20M | 9/21 | A ICU | R | R | I | R | I | R | I | 2 | 2 | RESP |
| 26 | 65F | 11/9 | C ICU | R | R | R | R | R | R | I | 2 | 3 | RESP |
| 27 | 71M | 9/6 | D WARD | S | I | I | S | S | R | R | 2 | URINE | |
| 28 | 45F | 9/16 | C ICU | S | S | R | R | S | R | R | 2 | RESP | |
| 29 | 50M | 3/11 | A ICU | R | R | R | R | R | R | R | 0.5 | 3 | URINE |
| 30 | 61F | 8/26 | D ICU | R | R | R | R | R | R | R | 1.5 | 2 | BLOOD |
| 31 | 78M | 11/10 | A WARD | S | R | I | R | S | R | R | 0.5 | 2 | URINE |
Study isolates (plus WC-31, which was isolated from a patient on Hospital Day 1 after transfer from an outside hospital). Legend WC = Weill Cornell; PT = Patient age and gender; Date: All dates are from 2008; Floor: Each letter represents a different hospital floor; Antimicrobial susceptibility to the various agents was determined following CLSI guidelines, or the Mean Inhibitory Concentration is reported directly for polymyxin B and tigecycline (µg/mL): A/S: ampicillin-sulbactam, Carb: imipenem or meropenem; Cef: cefepime; Gent; gentamicin; Amik: amikacin; S/T: sulfamethoxazole-trimethoprim; Levo: levofloxacin; PM: polymyxin B; Tig: tigecycline; Source: Resp = respiratory. Susceptibility interpretation based on 2008 CLSI cutoff points.
Figure 1Rep-PCR Analysis of Study Isolates.
Isolates with more than 90% similarity were considered related. Study isolates (WC 1–30) are shown, plus one isolate (WC-31) isolated on hospital day 1 after transfer from an outside hospital. Results show the majority of the study isolates are closely related.
Figure 2Integron Content in Select Study Isolates.
Integron PCR gene products of WC 13–24 are shown. The block arrow marks the 550 base pair PCR product of the prevalent strain A. baumannii. The water control is labeled “neg.” The cartoon shows the layout of a typical Class I integron. The PCR primers are presented by CS-F and CS-R.
Figure 3Metabolomic Analysis of Prevalent Endemic and Sporadic A. baumannii Isolates.
(A) Principal components analysis of prevalent endemic (black circles) and sporadic (gray circles) isolates (in which the metabolomic profile of each isolate is represented as a single point on a 3-D axis) shows significant overap, consistent with similar metabolic profiles. (B) Targeted analysis of intermediates of the Entner-Doudoroff (ED) pathway shows no change in abundance of ED metabolites in sporadic (gray) vs prevalent endemic (black) isolates. (C) Abundance of gluconolactone (a representative intermediate in the ED pathway) did not differ significantly between sporadic isolates (WC-1, WC-5, and WC-6) and prevalent endemic isolates (WC-9, WC-5, and WC-6).